1. Home
  2. ARQT vs AFYA Comparison

ARQT vs AFYA Comparison

Compare ARQT & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • AFYA
  • Stock Information
  • Founded
  • ARQT 2016
  • AFYA 1999
  • Country
  • ARQT United States
  • AFYA Brazil
  • Employees
  • ARQT N/A
  • AFYA N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • AFYA Other Consumer Services
  • Sector
  • ARQT Health Care
  • AFYA Real Estate
  • Exchange
  • ARQT Nasdaq
  • AFYA Nasdaq
  • Market Cap
  • ARQT 1.7B
  • AFYA 1.6B
  • IPO Year
  • ARQT 2020
  • AFYA 2019
  • Fundamental
  • Price
  • ARQT $13.04
  • AFYA $18.23
  • Analyst Decision
  • ARQT Strong Buy
  • AFYA Sell
  • Analyst Count
  • ARQT 6
  • AFYA 5
  • Target Price
  • ARQT $18.80
  • AFYA $17.60
  • AVG Volume (30 Days)
  • ARQT 2.1M
  • AFYA 146.5K
  • Earning Date
  • ARQT 05-06-2025
  • AFYA 05-08-2025
  • Dividend Yield
  • ARQT N/A
  • AFYA 1.27%
  • EPS Growth
  • ARQT N/A
  • AFYA 41.32
  • EPS
  • ARQT N/A
  • AFYA 1.31
  • Revenue
  • ARQT $212,819,000.00
  • AFYA $599,363,389.00
  • Revenue This Year
  • ARQT $61.15
  • AFYA $15.09
  • Revenue Next Year
  • ARQT $37.98
  • AFYA $9.07
  • P/E Ratio
  • ARQT N/A
  • AFYA $13.86
  • Revenue Growth
  • ARQT 100.03
  • AFYA 15.70
  • 52 Week Low
  • ARQT $6.99
  • AFYA $14.52
  • 52 Week High
  • ARQT $17.75
  • AFYA $19.90
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 40.51
  • AFYA 43.10
  • Support Level
  • ARQT $13.27
  • AFYA $18.35
  • Resistance Level
  • ARQT $14.30
  • AFYA $19.23
  • Average True Range (ATR)
  • ARQT 0.71
  • AFYA 0.66
  • MACD
  • ARQT -0.07
  • AFYA -0.16
  • Stochastic Oscillator
  • ARQT 10.94
  • AFYA 13.37

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.

Share on Social Networks: